{
  "meta": {
    "timestamp": "2025-01-06T14:17:49.647699",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Acelyrin Inc.",
      "symbol": "SLRN",
      "analysis": {
        "historical": {
          "risk_score": 70,
          "key_risks": [
            "Clinical trial failures, particularly the Phase 2b/3 trial for izokibep in uveitis",
            "Regulatory and development risks due to reliance on clinical trial success and approvals",
            "Financial dependence on external funding and high cash burn rates",
            "Pipeline concentration risk with heavy reliance on izokibep",
            "Operational risks highlighted by CRO errors in trial management"
          ],
          "controversies": [
            "Significant stock price drop following the failure of the Phase 2b/3 trial for izokibep",
            "Programming error by a contract research organization in a Phase 2b/3 trial"
          ],
          "environmental_issues": [],
          "social_issues": [],
          "governance_issues": [
            "Operational inefficiencies and risks in trial management"
          ],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program ...",
              "snippet": "Conference call to review unmet need in TED, new Phase 2 data and Phase 3 program design to be held today, January 6, 2025, at 4:30 PM ET. LOS ANGELES, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Acelyrin Inc. Acelyrin Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:31.100002+00:00",
              "published_date": null,
              "source_hash": "0720f0ecd966581965e8aa64d5ce03e8"
            },
            {
              "url": "",
              "title": "2025-01-06 | ACELYRIN, INC. Announces Additional Phase 2 ... - Stockhouse",
              "snippet": "Conference call to review unmet need in TED, new Phase 2 data and Phase 3 program design to be held today, January 6, 2025, at 4:30 PM ET LOS ANGELES, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Acelyrin Inc. Acelyrin Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:17:21.142952+00:00",
              "published_date": null,
              "source_hash": "ebbfefb07f2a343728d8a549902451a4"
            },
            {
              "url": "",
              "title": "ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program ...",
              "snippet": "Such risks and uncertainties include, without limitation, those associated with the successful completion of development and regulatory activities with respect to ACELYRIN's product candidates; maintaining and defending intellectual property protection; delays or failures to secure adequate supply of its product candidates; ACELYRIN's ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Acelyrin Inc. Acelyrin Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:17:21.142965+00:00",
              "published_date": null,
              "source_hash": "f01132b7a7686cd77ad8cd9b5fc7f088"
            },
            {
              "url": "",
              "title": "ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program ...",
              "snippet": "ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab GlobeNewswire 4d Hold Rating Maintained for ACELYRIN, INC.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Acelyrin Inc. Acelyrin Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:17:21.142977+00:00",
              "published_date": null,
              "source_hash": "337e6e52933e7ff58918b5d95849a87a"
            },
            {
              "url": "",
              "title": "What's Going On With ACELYRIN Shares Friday? - Benzinga",
              "snippet": "ACELYRIN, Inc. SLRN shares are moving higher on Friday after the company announced that it will reveal Phase 2 data for Subcutaneous Lonigutamab further supporting its potential for a best-in ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Acelyrin Inc. Acelyrin Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:17:21.142986+00:00",
              "published_date": null,
              "source_hash": "25d39262d1ca4557b2a0246ba76d8640"
            },
            {
              "url": "",
              "title": "ACELYRIN, INC. Announces Positive Top-line Results from Its Global ...",
              "snippet": "10-Q for the quarter ended September 30, 2023. Forward-looking statements contained in this press release are made as of this date, and ACELYRIN undertakes no duty to update such information except as required under applicable law. ACELYRIN, INC. Contact: investors@acelyrin.com media@acelyrin.com. Link annotation. Link annotation. Link annotation",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Acelyrin Inc. Acelyrin Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:17:21.142996+00:00",
              "published_date": null,
              "source_hash": "45b69a79c12c170cbb0d7c6a94c54d39"
            },
            {
              "url": "",
              "title": "ACELYRIN | Accelerating Life-Changing Medicines",
              "snippet": "acelyrin, inc. Reports Third Quarter 2024 Financial Results and Recent Highlights Topline data from Phase 2b/3 trial of izokibep as a treatment for non-infectious non-anterior uveitis expected in December 2024 Positive lonigutamab EOP2 FDA interaction completed...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Acelyrin Inc. Acelyrin Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:17:21.143007+00:00",
              "published_date": null,
              "source_hash": "c91247251ed92cd587758689854450fa"
            },
            {
              "url": "",
              "title": "ACELYRIN, INC. Announces Topline Results From Phase 2b/3 - GlobeNewswire",
              "snippet": "acelyrin, inc. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis December 10, 2024 16:30 ET | Source: ACELYRIN, INC.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Acelyrin Inc. Acelyrin Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:17:21.143016+00:00",
              "published_date": null,
              "source_hash": "4d278b42884feee5e2c2236bd7efcd78"
            },
            {
              "url": "",
              "title": "Acelyrin, Inc. - AnnualReports.com",
              "snippet": "ACELYRIN, INC. (Nasdaq: SLRN) is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. ACELYRIN's lead program, lonigutamab, is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Acelyrin Inc. Acelyrin Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:17:21.143023+00:00",
              "published_date": null,
              "source_hash": "63059be1fddfdc4f05fe5c18dd330f38"
            },
            {
              "url": "",
              "title": "ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming ...",
              "snippet": "ACELYRIN will forego hosting the previously scheduled Q1 2024 earnings call and the company will file the related 10-Q report no later than May 14, 2024. About ACELYRIN ACELYRIN, INC. (Nasdaq: SLRN) is a Los Angeles area-based late-stage clinical biopharma company with additional operations in the San",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Acelyrin Inc. Acelyrin Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:17:21.143032+00:00",
              "published_date": null,
              "source_hash": "808a30177117542fba6b3c8d08dfe931"
            },
            {
              "url": "",
              "title": "Why Is Acelyrin, Inc. (SLRN) Among the Best Biotech Penny Stocks to Invest in Now?",
              "snippet": "We recently published a list of the 12 Best Biotech Penny Stocks To Invest In Now. In this article, we are going to take a look at where Acelyrin, Inc. (NASDAQ:SLRN) stands against the other best biotech penny stocks to invest in now.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Acelyrin Inc. Acelyrin Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:17:29.663871+00:00",
              "published_date": "2024-12-30T19:55:06+00:00",
              "source_hash": "525fad7a009da25010b277b0539da314"
            },
            {
              "url": "",
              "title": "What's Going On With ACELYRIN Shares Friday?",
              "snippet": "ACELYRIN shares are moving higher on Friday after the company announced that it will reveal Phase 2 data and announce Phase 3 plans for Subcutaneous Lonigutamab at a virtual investor event.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Acelyrin Inc. Acelyrin Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:17:24.236798+00:00",
              "published_date": "2025-01-03T17:52:00+00:00",
              "source_hash": "77b3dc18772c3d508d69d9b537884b63"
            },
            {
              "url": "",
              "title": "ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab",
              "snippet": "Dr. Kossler received her MD from the Georgetown School of Medicine and completed her ophthalmology residency and oculofacial plastic and orbital surgery fellowship at the Bascom Palmer Eye Institute.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Acelyrin Inc. Acelyrin Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:33.867514+00:00",
              "published_date": "2025-01-03T02:00:00+00:00",
              "source_hash": "bb6fb6235755d9096b6c0e053be18a63"
            },
            {
              "url": "",
              "title": "Charles Schwab Investment Management Inc. Has $3.01 Million Stock Position in Acelyrin, Inc. (NASDAQ:SLRN)",
              "snippet": "Charles Schwab Investment Management Inc.'s holdings in Acelyrin were worth $3,006,000 as of its most recent SEC filing. Other large investors also recently made changes to their positions in ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Acelyrin Inc. Acelyrin Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:33.867538+00:00",
              "published_date": "2024-12-15T00:00:00+00:00",
              "source_hash": "281faeb304e0fd75a3e8d99613773ac2"
            },
            {
              "url": "",
              "title": "ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis",
              "snippet": "About ACELYRIN, INC. ACELYRIN ... with the successful completion of development and regulatory activities with respect to lonigutamab; maintaining and defending intellectual property protection; delays or failures to secure adequate supply of lonigutamab ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Acelyrin Inc. Acelyrin Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:17:24.236833+00:00",
              "published_date": "2024-12-11T05:30:00+00:00",
              "source_hash": "fb187c19ed353c5d6b600f1aa0873de8"
            },
            {
              "url": "",
              "title": "Acelyrin fails late-phase clinical trial months after $540M IPO",
              "snippet": "Acelyrin has given its investors a nasty shock. Months after raising $540 million in a rare biotech IPO, the company has reported the failure of its lead prospect in a phase 2b/3 inflammatory ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Acelyrin Inc. Acelyrin Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:17:27.029962+00:00",
              "published_date": null,
              "source_hash": "58bf6254313d15ca2bc22b55ba93e5c1"
            },
            {
              "url": "",
              "title": "Could a CRO error explain Acelyrin's shocking phase 3 failure?",
              "snippet": "Acelyrin sent a chill rippling through the IPO market in September when its phase 3 clinical trial unexpectedly failed. But now the company says some errors by the contract research organization ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Acelyrin Inc. Acelyrin Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:31.100034+00:00",
              "published_date": null,
              "source_hash": "cfb416f32635d6eb1ecc3e46cc9438a8"
            },
            {
              "url": "",
              "title": "Acelyrin's skin disease drug trial failure wipes off IPO gains",
              "snippet": "Acelyrin was one of the few biotech companies to go public this year, raising $540 million in its debut, the second biggest initial public offering (IPO) in the sector after Kenvue , opens new tab.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Acelyrin Inc. Acelyrin Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:17:27.030085+00:00",
              "published_date": null,
              "source_hash": "7ea7e095fef943125a1c8a7dee3f8407"
            },
            {
              "url": "",
              "title": "CRO disputes Acelyrin's implication of trial misconduct",
              "snippet": "The study failure in September was notable news, as it came just months after Acelyrin debuted on the market with the largest biotech initial public offering in more than two years. At the time, Acelyrin said the trial's results showed signs its drug was effective at treating a skin condition called hidradenitis suppurativa.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Acelyrin Inc. Acelyrin Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:17:27.030094+00:00",
              "published_date": null,
              "source_hash": "72d5ddf7db3fb46eb7fdb9ebaa6491d2"
            },
            {
              "url": "",
              "title": "After IPO success, Acelyrin hits trial setback with inflammation drug",
              "snippet": "Acelyrin's share value collapsed Tuesday after its lead drug fell short in the company's first big trial test since it raised $540 million in a May IPO. ... Shares in Acelyrin fell by more than half the morning after the company disclosed clinical trial results.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Acelyrin Inc. Acelyrin Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:17:27.030103+00:00",
              "published_date": null,
              "source_hash": "20779fbb1e3296bf17c41361e23a2ac8"
            },
            {
              "url": "",
              "title": "ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of ...",
              "snippet": "About the Phase 2b/3 Uveitis Clinical Trial and Topline Results: The Phase 2b/3 clinical trial (NCT05683496) evaluated izokibep versus placebo in non-infectious, non-anterior uveitis. Patients in the study were randomized 1:1 to receive weekly subcutaneous injections of izokibep 160 mg or placebo. ... ACELYRIN's failure to realize the ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Acelyrin Inc. Acelyrin Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:17:27.030113+00:00",
              "published_date": null,
              "source_hash": "6047a39697f86f3fe34224199cebb3c1"
            },
            {
              "url": "",
              "title": "ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of ...",
              "snippet": "$562.4 million in cash, cash equivalents, and short-term marketable securities on September 30, 2024 projected to provide runway to mid-2027, including completion of planned Phase 3 trials and BLA-enabling activities for lonigutamab as well as selective pipeline expansion. LOS ANGELES, Dec. 10, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Acelyrin Inc. Acelyrin Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:17:27.030124+00:00",
              "published_date": null,
              "source_hash": "aa830b38e8396acaf56bfa311e4fdd47"
            },
            {
              "url": "",
              "title": "ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming ...",
              "snippet": "product candidates; the timing and results of ACELYRIN s clinical trials, including the risk that future clinical trial results could differ materially and adversely from prior clinical trial results or data; maintaining and defending intellectual property protection; delays or failures to secure adequate",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Acelyrin Inc. Acelyrin Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:17:27.030133+00:00",
              "published_date": null,
              "source_hash": "f73e17ae44b536521e19b8fe87913a85"
            },
            {
              "url": "",
              "title": "ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b ...",
              "snippet": "ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in ... global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA) will be shared as a late breaking oral presentation at the 2024 European Alliance ... ACELYRIN s failure to realize the expected benefits of its acquisition of additional ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Acelyrin Inc. Acelyrin Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:17:27.030142+00:00",
              "published_date": null,
              "source_hash": "ac2ebb48e68317e0bf1904cc2fcd8477"
            },
            {
              "url": "",
              "title": "ACELYRIN Halts Izokibep Development After Phase 2b/3 Uveitis Trial Fails: Stock Down",
              "snippet": "(RTTNews) - Shares of ACELYRIN, Inc. (SLRN) are down over 17% in premarket ... In the Phase 2b/3 clinical trial of Izokibep in uveitis, neither the primary endpoint nor secondary endpoints were ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Acelyrin Inc. Acelyrin Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:17:29.663767+00:00",
              "published_date": "2024-12-11T11:04:00+00:00",
              "source_hash": "7d9852de9ab75576f6c844fe2441505c"
            },
            {
              "url": "",
              "title": "ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis",
              "snippet": "LOS ANGELES, Dec. 10, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq ... About the Phase 2b/3 Uveitis Clinical Trial and Topline Results: The Phase 2b/3 clinical trial (NCT05683496) evaluated ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Acelyrin Inc. Acelyrin Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:17:29.663860+00:00",
              "published_date": "2024-12-10T21:35:00+00:00",
              "source_hash": "4d823a3bc5644333e0ec9da0a2c81fa1"
            },
            {
              "url": "",
              "title": "Acelyrin, Inc. (SLRN)",
              "snippet": "LOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage ... including completion of planned Phase 3 trials and BLA-enabling activities for lon As the U.S ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Acelyrin Inc. Acelyrin Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:17:29.663881+00:00",
              "published_date": "2025-01-02T00:00:00+00:00",
              "source_hash": "7658f016f29b244455636e0d2d8edf11"
            },
            {
              "url": "",
              "title": "Acelyrin Reveals Programming Error In Arthritis Drug Trial",
              "snippet": "Importantly, there is no risk to patient safety resulting from the sequencing errors and no patient received more active treatment than was already included in the protocol for the most frequent ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Acelyrin Inc. Acelyrin Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:31.099885+00:00",
              "published_date": null,
              "source_hash": "c1283c473bb19e8dfd86abce85d510c1"
            },
            {
              "url": "",
              "title": "ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program ...",
              "snippet": "acelyrin, inc. (Nasdaq: SLRN) is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Acelyrin Inc. Acelyrin Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:31.099988+00:00",
              "published_date": null,
              "source_hash": "6b4b88e9f5b602a475f380b37bd9881c"
            },
            {
              "url": "",
              "title": "Accelerating Medicines to Transform Patients' Lives - ACELYRIN, INC.",
              "snippet": "Such forward-looking statements reflect the current views of ACELYRIN with respect to future events, and are subject to known and unknown risks (including, without limitation, business, regulatory, economic and ... Minimize Safety Risks. Patient-Centric Convenient Administration. Maintains homeostatic IGF-1. Potential Patient Benefits",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Acelyrin Inc. Acelyrin Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:31.100013+00:00",
              "published_date": null,
              "source_hash": "b7eb4383bc07fcc8cae41b71031d3920"
            },
            {
              "url": "",
              "title": "Acelyrin shifts from main drug, lays off staff - BioPharma Dive",
              "snippet": "Acelyrin is also shelving another, much earlier-stage drug called SLRN-517. The restructuring moves have led the company to cut one-third of its workforce, or about 43 employees, based on its headcount as of March 15, 2024. The company's focus will now shift to lonigutamab, results for which Acelyrin disclosed in March. Testing showed it was ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Acelyrin Inc. Acelyrin Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:31.100025+00:00",
              "published_date": null,
              "source_hash": "15ffb80c7ff8c31e104dc8106060d364"
            },
            {
              "url": "",
              "title": "ACELYRIN, INC. Announces Additional Phase 2 Data and Phase - GlobeNewswire",
              "snippet": "acelyrin, inc. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease January 06, 2025 16:00 ET | Source: ACELYRIN, INC.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Acelyrin Inc. Acelyrin Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:31.100042+00:00",
              "published_date": null,
              "source_hash": "765cbdde3eb464578c32357d88d43b1d"
            },
            {
              "url": "",
              "title": "ACELYRIN | Accelerating Life-Changing Medicines",
              "snippet": "ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Loni... LOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transf...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Acelyrin Inc. Acelyrin Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:31.100051+00:00",
              "published_date": null,
              "source_hash": "54e4eb97e06c26feb767cf7f37747842"
            },
            {
              "url": "",
              "title": "ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 ...",
              "snippet": "Rapid-fire Oral Presentation to Highlight Efficacy, Safety, and Quality of Life Outcomes LOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Acelyrin Inc. Acelyrin Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:31.100060+00:00",
              "published_date": null,
              "source_hash": "85fb632f4ef963d193b0403cf9379c63"
            },
            {
              "url": "",
              "title": "ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring ...",
              "snippet": "ACELYRIN, INC. Experts and advocates to provide important strategic input and clinical expertise as ACELYRIN completes its Phase 2 trial of lonigutamab in TED and prepares to initiate Phase 3 ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Acelyrin Inc. Acelyrin Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:31.100068+00:00",
              "published_date": null,
              "source_hash": "d8b2aab39bed499289b9f58aa64e67aa"
            },
            {
              "url": "",
              "title": "ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis",
              "snippet": "Izokibep was well-tolerated in the trial, with a safety profile consistent with previous data ... that its existing cash resources will provide runway to mid-2027. About ACELYRIN, INC. ACELYRIN, INC. (Nasdaq: SLRN) is focused on providing patients life ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Acelyrin Inc. Acelyrin Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:33.867549+00:00",
              "published_date": "2024-12-10T00:00:00+00:00",
              "source_hash": "ef50f2584147e3f64cd22562fdc9e7c2"
            },
            {
              "url": "",
              "title": "ACELYRIN acquires ValenzaBio, strengthens immunology position",
              "snippet": "ACELYRIN, Inc., a Los Angeles area-based ... with moderate-to-severe Hidradenitis Suppurativa (HS), following a 30-patient open-label Part A of a phase 2b/3 trial, the top-line 12-week data ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Acelyrin Inc. Acelyrin Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:33.867559+00:00",
              "published_date": "2025-01-06T00:00:00+00:00",
              "source_hash": "80179a48c175ddd91f0513530cef2648"
            },
            {
              "url": "",
              "title": "Acelyrin, Inc. (SLRN)",
              "snippet": "Rapid-fire Oral Presentation to Highlight Efficacy, Safety, and Quality of Life Outcomes LOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Acelyrin Inc. Acelyrin Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:33.867568+00:00",
              "published_date": "2025-01-02T00:00:00+00:00",
              "source_hash": "ea0c10d9d48257c744892af4308b3f96"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Acelyrin Inc. regulatory approval delays",
              "rationale": "Investigate potential delays or issues in obtaining FDA or EMA approvals for izokibep",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "Acelyrin Inc. clinical trial failures",
              "rationale": "Look for any reports or data on failed clinical trials for izokibep or other pipeline candidates",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "Acelyrin Inc. patient safety concerns",
              "rationale": "Search for any ethical concerns or patient safety issues related to Acelyrin's clinical trials or therapies",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T14:17:49.647707",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}